Wanted: “Imaginative and Original Thoughts” On Coverage With Evidence Development
This article was originally published in RPM Report
The Centers for Medicare & Medicaid Services is revisiting its policy on Coverage with Evidence Development. Here is how two key officials from CMS’ Coverage & Analysis Group described their thinking during a conversation with The RPM Report as part of the FDA/CMS Summit for Biopharma Executives in December.
You may also be interested in...
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
White House Council of Economic Advisors says US House drug price “negotiation” bill will reduce the number of innovative medicines by 100 over a decade; the Congressional Budget Office says more like 8-15. Both analyses miss the point – but also show that industry is losing a crucial piece of political ground.
The FDA has confirmed the picks to head most of the new offices in the restructured drug review organization, with one notable exception. The choice for the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine is still pending, while one candidate – Hylton Joffe – will be serving as acting OND deputy director.